FDA-approved
Heart & blood
Motixafortide
Evidence
FDA approved
Class
CXCR4 antagonist peptide
KEY TAKEAWAY
Motixafortide is a synthetic cyclic peptide that blocks the CXCR4 receptor. It is sold as Aphexda. The FDA approved motixafortide (Aphexda) in September 2023, used with filgrastim, to mobilize stem cells in multiple myeloma.
Written by the Veylo editorial team · Updated
November 2026
What it is
CXCR4 antagonist peptide
Approved for
Mobilizing stem cells for transplant in multiple myeloma
Key fact
The FDA approved motixafortide (Aphexda) in September 2023, used with filgrastim, to mobilize stem cells in multiple myeloma.
Route
Subcutaneous injection
Evidence strength
FDA approved
Motixafortide is a synthetic cyclic peptide that blocks the CXCR4 receptor. It is sold as Aphexda.
It releases stem cells from the bone marrow into the blood, where they can be collected for a transplant.
The FDA approved motixafortide (Aphexda) in September 2023, used with filgrastim, to mobilize stem cells in multiple myeloma.
Mobilizing stem cells for transplant in multiple myeloma.
Injection-site reactions, itching, flushing and back pain are common. Serious allergic reactions can occur.
U.S. FDA prescribing information for Motixafortide. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.